New indication granted for immune globulin
Rhophylac, an anti-D Rh immunoglobulin, has been approved by the FDA for the treatment of immune thrombocytopenic purpura (ITP)
Rhophylac, an anti-D Rh immunoglobulin, has been approved by the FDA for the treatment of immune thrombocytopenic purpura (ITP). According to manufacturer CSL Behring, the immune globulin will raise platelet counts in Rh(0)(D)-positive, nonsplenectomized adult patients with chronic ITP and must be administered intravenously for the new indication. Rhophylac was previously approved for suppression of Rh isoimmunization in pregnancy and obstetric conditions and for incompatible transfusions in Rh(0)(D)-negative individuals transfused with blood components containing Rh(0)(D)-positive red blood cells.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
